KDR and colorectal carcinoma: The trastuzumab (anti-HER2), cetuximab (anti-EGFR), panitumumab (anti-EGFR), ramucirumab (anti-VEGFR2), and bevacizumab (anti-VEGF-A) are commercial specific monoclonal antibodies that are currently used in CRC treatment (170).